Oct 9, 2019 by David Haen3 Companies To Watch For At November’s Society for Immunotherapy of Cancer MeetingDue to the explosion in immuno-oncology in recent years, what was once a small scientific meeting near the end of the year has become a go-to event for drug developers.
Oct 8, 2019 by David HaenIs Qiagen’s Stumble An Opportunity For Investors?Investors are wondering whether to welcome or fear Qiagen’s recent announcement about its CEO’s departure, slowing sales, and business restructuring.
Oct 7, 2019 by David HaenAre These 3 Recent Biotech IPOs a Good Deal for Investors?Three biotech companies successfully completed IPOs last week. Would investors have been better off buying shares on the open market?
Oct 4, 2019 by David Haen3 Mid-Cap Biotech Stocks To Consider Buying NowThese revenue-producing, possible acquisition candidates may be the right medicine to heal your portfolio.
Oct 2, 2019 by David HaenAre There Good Investments Among 2019's Biotech IPOs?Investing in biotechs is inherently risky. IPOs are too. What does the stock performance of 2019’s biotech IPO class look like so far?
Oct 1, 2019 by David HaenA Cancer Diagnostics Company You Should Own TodaySince the start of September, the luster has disappeared from Exact Sciences' stock. This pullback provides an opportunity to own a company that is growing on multiple levels.
Sep 30, 2019 by David Haen2 Biotechs Tackling the Challenge of Lou Gehrig’s DiseaseHistorically, the underlying cause of ALS has evaded researchers, except in rare genetic cases. But more light has been shone on the disease and the potential of new avenues for drug intervention.
Sep 27, 2019 by David HaenCancer Results to Watch at This Weekend’s European Society of Medical Oncology CongressDoctors, researchers, and pharmaceutical experts will converge upon Barcelona to share the latest results in cancer research. Here is a run-down on three to watch.
Sep 25, 2019 by David Haen4 Mid-Market Banks Powering Advancements In HealthcareInnovation needs capital. Discovering and developing new medicines requires lots of it. Let's explore a few investment banks helping to fund these advancements.
Sep 20, 2019 by David Haen6 September Healthcare IPOs Investors Should Take Stock OfThe recent crop of new stocks runs the gamut from R&D stage biotech to a Fortune 500 spin-off with billions in revenue.
Sep 19, 2019 by David Haen3 Ways to Gain Exposure to Venture Capital in Tech and HealthcareInvesting in companies that provide growth capital to promising start-ups can be financially rewarding.
